Autoimmunity: The Why of the Why
Understanding why the immune system attacks self—from failed tolerance checkpoints to molecular mimicry, disease clustering, and the rationale behind immunosuppressive therapy
The Central Paradox of Autoimmunity
The adaptive immune system generates 1015 unique receptors through random somatic recombination. This astronomical diversity ensures we can recognize virtually any pathogen—but it also guarantees that some receptors will recognize self-antigens. The fundamental question is not "why does autoimmunity occur?" but rather "why doesn't autoimmunity happen to everyone?"
Random TCR/BCR generation is mathematically certain to produce self-reactive clones. Evolution solved this by creating a multi-layered tolerance system—a series of checkpoints that eliminate or inactivate autoreactive lymphocytes before they can cause damage. Autoimmunity is not a failure of the immune system to work; it's a failure of these tolerance checkpoints.
Thymus / Bone Marrow
Lymph Nodes / Tissues
Why Tolerance Fails
- Genetic susceptibility: HLA polymorphisms alter self-peptide presentation
- AIRE mutations: Incomplete thymic expression of peripheral antigens
- PTPN22 variants: Altered TCR/BCR signaling thresholds
- Environmental triggers: Infections, drugs, tissue damage
- Molecular mimicry: Cross-reactive epitopes between pathogens and self
- Treg dysfunction: FOXP3 mutations (IPEX), IL-2 deficiency
- Bystander activation: Tissue damage exposes sequestered antigens
Why Specific Organs Are Targeted
- HLA restriction: Specific HLA alleles present specific tissue antigens preferentially
- Tissue-specific antigens: Some organs express unique proteins (thyroid, pancreas)
- Vascular access: Some tissues are more accessible to immune surveillance
- Local inflammation: Prior injury can break immunological ignorance
- Epitope spreading: Initial damage releases additional autoantigens
- Loss of immune privilege: Eye, CNS, testes have special barriers
Understanding tolerance mechanisms explains why autoimmune diseases: (1) cluster in families and with specific HLA types, (2) often follow infections or tissue injury, (3) can spread to involve additional autoantigens over time (epitope spreading), and (4) respond to immunosuppression but require chronic therapy since the underlying tolerance defect persists.
Central Tolerance
The primary checkpoint: How T cells are educated in the thymus and B cells in the bone marrow to distinguish self from non-self
T Cell Central Tolerance: The Thymic Academy
T Cell Development & Selection in the Thymus
Pro-T Cell
TCR rearrangement begins
DP Thymocyte
CD4+CD8+ stage
Positive Selection
MHC recognition
(Cortex - cTECs)
Negative Selection
Self-reactive = death
(Medulla - mTECs)
Mature T Cell
CD4+ or CD8+ SP
T cells can only "see" antigen presented on MHC molecules. If a T cell's TCR cannot recognize self-MHC at all, it will be useless in the periphery—unable to interact with any antigen-presenting cell. Positive selection ensures that only T cells capable of recognizing self-MHC survive. This happens in the thymic cortex where cortical thymic epithelial cells (cTECs) express MHC I and II. T cells that fail to recognize MHC die by "death by neglect" (no survival signal).
A TCR that recognizes self-MHC + self-peptide with high affinity would attack normal tissues. Negative selection eliminates these dangerous clones. This happens in the thymic medulla where medullary thymic epithelial cells (mTECs) present self-peptides. High-affinity binding → apoptosis (clonal deletion). The challenge: How can mTECs present tissue-specific antigens they don't normally express?
AIRE: The Master Regulator of Central Tolerance
AIRE (Autoimmune Regulator) is a transcription factor expressed in medullary thymic epithelial cells (mTECs). It enables the "promiscuous gene expression" of thousands of tissue-restricted antigens (TRAs)—proteins normally expressed only in specific peripheral tissues like insulin (pancreas), thyroglobulin (thyroid), or myelin (CNS).
The thymus must teach T cells about every self-antigen in the body—but how can a single organ know what proteins are expressed in the eye, pancreas, or liver? AIRE solves this by activating transcription of these tissue-specific genes within the thymus itself. This creates a "mirror" of the peripheral self that developing T cells can be tested against.
- Chromatin binding: AIRE preferentially binds to genes with H3K4me0 (unmethylated histones)—marks of transcriptionally inactive genes
- DNA-PK recruitment: Creates double-strand breaks, relaxing chromatin structure
- RNA Pol II activation: Releases stalled polymerase to enable transcription elongation
- Stochastic expression: Each mTEC expresses ~1-3% of AIRE-dependent genes (but collectively, the mTEC population covers the entire repertoire)
Autoimmune Polyglandular Syndrome Type 1 (APS-1) results from AIRE mutations. Without AIRE, mTECs fail to express tissue-restricted antigens → autoreactive T cells escape to the periphery → multiple organ-specific autoimmunity. Classic triad: chronic mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency. Additional manifestations: type 1 diabetes, autoimmune hepatitis, vitiligo, alopecia.
B Cell Central Tolerance: The Bone Marrow Checkpoint
B Cell Tolerance Mechanisms in Bone Marrow
Immature B Cell
Surface IgM expressed
Self-Antigen
Recognition?
BCR binds self
Receptor Editing
New light chain
(Primary mechanism)
Clonal Deletion
If editing fails
→ Apoptosis
Anergy
If soluble antigen
→ Functional silence
B cell development is energetically expensive. Each B cell undergoes complex V(D)J recombination to generate a unique BCR. If every autoreactive B cell were simply deleted, the system would lose tremendous diversity. Receptor editing offers a second chance: the autoreactive B cell can rearrange a new light chain, changing its BCR specificity. Only if editing fails to produce a non-autoreactive receptor does deletion occur.
- RAG re-expression: Self-antigen recognition maintains RAG1/RAG2 expression
- Secondary κ rearrangement: Uses downstream Jκ segments to replace autoreactive Vκ
- λ chain switch: If κ editing exhausted, can switch to λ locus
- ~25-50% of B cells undergo editing during normal development
- Editing is the dominant mechanism; deletion is a backup when editing fails
| Mechanism | Trigger | Outcome | Clinical Relevance |
|---|---|---|---|
| Receptor Editing | BCR binds membrane-bound self-antigen | New light chain, changed specificity | Defective editing → anti-DNA antibodies in SLE |
| Clonal Deletion | High-affinity multivalent self-antigen | Apoptosis (BIM-mediated) | Escape → organ-specific autoantibodies |
| Anergy | Soluble monovalent self-antigen | Functionally silenced, reduced IgM | Anergic B cells can reactivate in inflammation |
Peripheral Tolerance
The safety net: How self-reactive lymphocytes that escape central tolerance are controlled in the periphery
Why Peripheral Tolerance Is Essential
Central tolerance is only 60-70% efficient. Self-reactive T and B cells regularly escape to the periphery. Furthermore, some self-antigens are never expressed in the thymus or bone marrow (cryptic antigens, post-translationally modified proteins). Peripheral tolerance provides a multi-layered safety net to prevent these escaped cells from causing autoimmunity.
Anergy
Functional unresponsiveness induced when T cells recognize antigen without costimulation.
Signal 1 without Signal 2: TCR engagement (Signal 1) without CD28 costimulation (Signal 2) leads to NFAT activation but not AP-1 activation. NFAT alone induces:
- Expression of anergy-promoting genes (GRAIL, Cbl-b, Itch)
- Epigenetic silencing of IL-2 and effector cytokine genes
- Upregulation of inhibitory receptors (CTLA-4, PD-1)
In steady state, APCs present self-antigens without danger signals → no costimulatory molecule upregulation. T cells that see antigen this way become anergic. This ensures that T cells only activate when there's both antigen AND danger (infection/inflammation).
Regulatory T Cells
CD4+CD25+FOXP3+ cells that actively suppress autoreactive effector cells.
- IL-2 consumption: High CD25 expression depletes IL-2 from microenvironment
- Inhibitory cytokines: IL-10, TGF-β, IL-35 suppress effector function
- CTLA-4: Strips CD80/86 from APCs (trans-endocytosis)
- Granzyme/Perforin: Direct cytotoxicity against effector cells
- IDO induction: Tryptophan depletion in APCs
FOXP3 mutations → no functional Tregs → IPEX syndrome (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked). Fatal multi-organ autoimmunity in infancy without HSCT.
Checkpoint Molecules
Inhibitory receptors that prevent excessive T cell activation.
| CTLA-4 | Early phase (priming) | Lymph nodes |
| PD-1 | Late phase (effector) | Peripheral tissues |
CTLA-4 prevents initial T cell activation by competing with CD28 for B7 ligands—stops autoimmunity at the source. PD-1 limits T cells already in tissues, preventing damage during chronic antigen exposure. Together, they create redundant safeguards.
Immune Privilege: Protected Sites
Certain anatomical sites are protected from immune surveillance—not because they lack antigens, but because immune responses in these locations would cause catastrophic damage.
The eye, brain, and testes contain irreplaceable, non-regenerating tissues. Inflammation in these sites could cause blindness, paralysis, or infertility. Evolution created special barriers and immunosuppressive mechanisms to prevent immune responses here—even at the cost of being more vulnerable to infections.
- Blood-tissue barriers: Blood-brain barrier, blood-testis barrier, blood-retinal barrier
- Local immunosuppression: Constitutive TGF-β, FasL expression induces apoptosis of infiltrating T cells
- Low MHC expression: Reduced antigen presentation capacity
- ACAID: Anterior chamber-associated immune deviation induces regulatory responses
Sympathetic ophthalmia: Trauma to one eye releases sequestered ocular antigens → immune response damages the other eye. A dramatic example of what happens when immune privilege is broken.
Molecular Mimicry
When microbial antigens look like self: How infections trigger autoimmunity through cross-reactive immune responses
The Concept of Molecular Mimicry
T cell and B cell receptors do not recognize entire proteins—they recognize short peptide sequences (epitopes). If a microbial peptide shares structural or sequence similarity with a self-peptide, immune responses generated against the pathogen may cross-react with host tissues. The pathogen is cleared, but the autoimmune attack continues because the self-antigen persists.
Molecular Mimicry Cascade
Infection
Pathogen enters host
Immune Response
T/B cell activation
against pathogen
Cross-Reactivity
Epitope similarity
to self-antigen
Autoimmune Attack
Self-tissue damage
by cross-reactive cells
Chronic Disease
Self-antigen persists
→ ongoing attack
Classic Example: Rheumatic Fever
Group A Streptococcus (GAS) pharyngitis triggers cross-reactive antibodies and T cells that attack heart, brain, joints, and skin—the classic rheumatic fever.
- M protein α-helix → Cardiac myosin, laminin, vimentin (heart)
- Group A carbohydrate → N-acetyl-glucosamine in valve glycoproteins
- M protein epitopes → Lysoganglioside, dopamine receptors (brain)
- Hyaluronic acid capsule → Joint synovium
Anti-streptococcal antibodies bind valve endothelium → activate VCAM-1 → T cell infiltration → granulomatous inflammation (Aschoff bodies). The valve damage exposes collagen, triggering additional (non-cross-reactive) anti-collagen antibodies → progressive valve destruction even without recurrent infection.
Anti-streptococcal antibodies cross-react with basal ganglia neurons, binding to lysoganglioside and activating CaMKII signaling. This causes dopamine release and the involuntary "piano-playing" movements characteristic of chorea. Same mechanism underlies PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections).
Other Examples of Molecular Mimicry
| Disease | Trigger | Mimicry Target | Self-Antigen |
|---|---|---|---|
| Guillain-Barré Syndrome | Campylobacter jejuni | Lipooligosaccharide | GM1 ganglioside (peripheral nerve myelin) |
| Multiple Sclerosis | EBV (EBNA-1) | EBNA-1 peptides | Myelin basic protein, GlialCAM |
| Type 1 Diabetes | Coxsackievirus B | Viral protein 2C | GAD65 (glutamic acid decarboxylase) |
| Reactive Arthritis | Chlamydia, Salmonella | Bacterial HSP60 | Human HSP60 (synovium) |
| Autoimmune Myocarditis | Coxsackievirus B3 | Viral capsid protein | Cardiac myosin |
Molecular mimicry alone is not sufficient to cause autoimmunity. Additional factors required:
- Genetic susceptibility: Specific HLA alleles that can present the mimicking peptide
- Epitope spreading: Initial damage releases additional self-antigens
- Bystander activation: Inflammatory milieu activates dormant autoreactive cells
- Failure of peripheral tolerance: Treg dysfunction, insufficient anergy induction
Why Autoimmune Diseases Cluster
Understanding polyautoimmunity: Why having one autoimmune disease increases risk for others
The Phenomenon of Polyautoimmunity
Polyautoimmunity (≥2 autoimmune diseases) occurs in ~34% of autoimmune patients. Multiple Autoimmune Syndrome (≥3 diseases) follows specific clustering patterns. This is not random co-occurrence—it reflects shared genetic susceptibility genes, common pathways of immune dysregulation, and overlapping environmental triggers. The presence of one autoimmune disease indicates a fundamental defect in tolerance mechanisms that predisposes to others.
Mostly organ-specific, HLA-DR3/DR4 associated
Mostly systemic, HLA-DR2/DR3 associated
Shared Genetic Susceptibility
HLA Associations
HLA genes account for 20-60% of genetic risk for autoimmune diseases. Specific alleles show strong associations:
| HLA Allele | Associated Diseases |
|---|---|
| HLA-DR3 | T1D, SLE, Sjögren's, Graves', Celiac, MG |
| HLA-DR4 | RA, T1D, Pemphigus |
| HLA-B27 | Ankylosing Spondylitis, Reactive Arthritis, Uveitis |
| HLA-DQ2/DQ8 | Celiac Disease, T1D |
HLA molecules determine which peptides are presented to T cells. Specific HLA alleles may preferentially bind and present certain autoantigens, or may present microbial peptides that mimic self. The "shared epitope" hypothesis in RA: specific amino acids at positions 70-74 of HLA-DRβ chain create a binding pocket that presents arthritogenic peptides.
Non-HLA Shared Genes
- PTPN22: Phosphatase regulating TCR/BCR signaling → T1D, RA, SLE, Graves', MG
- CTLA4: T cell inhibitory receptor → T1D, Graves', RA, Celiac
- IL2RA (CD25): Treg function → T1D, MS, RA
- STAT4: Cytokine signaling → SLE, RA, Sjögren's
- TNFAIP3 (A20): NF-κB regulation → RA, SLE, Celiac, Psoriasis
- IRF5: Type I IFN pathway → SLE, RA, Sjögren's
These genes regulate fundamental tolerance mechanisms—TCR/BCR signaling thresholds, Treg function, cytokine responses. Variants that impair these pathways don't cause one specific disease; they create a general susceptibility to any autoimmune disease. The specific disease that develops depends on additional factors: other genes, HLA type, environmental triggers.
When diagnosing one autoimmune disease, actively screen for others. Patients with T1D should be screened for thyroid autoantibodies and celiac antibodies. Patients with SLE should be evaluated for Sjögren's and APS. This clustering is not coincidence—it reflects shared pathophysiology. The term "secondary autoimmune disease" is a misnomer; these are coexisting manifestations of a shared tolerance defect.
Rationale of Immunosuppression
Why we target specific pathways: Mechanistic basis for immunosuppressive therapies in autoimmune disease
The Three-Signal Model & Drug Targets
T Cell Activation Signals & Therapeutic Targets
Signal 1
TCR + Antigen/MHC
Target: Calcineurin
Signal 2
CD28 + B7 (Costim.)
Target: CTLA-4-Ig
Signal 3
Cytokine-driven
proliferation
Target: mTOR, JAK
Effector Function
Cytokines, cytotoxicity
Target: Anti-TNF, IL-6R
Autoimmune diseases result from failure of tolerance—not from having "too much" immune system. However, we cannot easily restore tolerance in established disease. Instead, we suppress the effector mechanisms that cause tissue damage while accepting increased infection risk. The goal is to interrupt the autoimmune cascade at strategic points while preserving enough immunity for host defense.
Mechanism: Block calcineurin phosphatase → prevent NFAT dephosphorylation → NFAT cannot enter nucleus → no IL-2 transcription → T cells cannot proliferate
Calcineurin is the bottleneck for T cell activation. Blocking it stops proliferation of all T cells—including autoreactive ones. Caveat: Also blocks Tregs, which depend on similar signaling. May not promote tolerance.
Mechanism: Inhibit mTORC1 → block cytokine-driven T cell proliferation → arrest cell cycle in G1 phase
Unlike calcineurin inhibitors, mTOR inhibitors spare Tregs. Tregs use oxidative phosphorylation (not mTOR-dependent glycolysis) for metabolism. Rapamycin can even expand Tregs relative to effector T cells → may promote tolerance rather than just suppression.
Mechanism: Block Janus kinases → prevent cytokine receptor signal transduction → inhibit downstream STAT activation
Different JAKs transduce signals from different cytokines. JAK1/JAK3 → IL-2, IL-6, IFN-γ. JAK2 → GM-CSF, erythropoietin. TYK2 → IL-12, IL-23, type I IFN. Selective JAK inhibitors can target specific cytokine pathways relevant to each disease.
Mechanism: CTLA-4 fusion protein binds CD80/86 on APCs → blocks CD28 costimulation → T cells receive Signal 1 without Signal 2 → anergy induction
This mechanism mimics natural peripheral tolerance (Signal 1 without Signal 2 = anergy). May induce IDO expression in APCs. Unlike calcineurin inhibitors, may actually promote long-term tolerance rather than temporary suppression.
Mechanism: Deplete CD20+ B cells via ADCC, CDC, and direct apoptosis → reduced autoantibody production, antigen presentation, cytokine secretion
B cells do more than make antibodies. They present antigen to T cells and produce cytokines. Surprisingly, B cell depletion often works even when autoantibody levels don't change—because it eliminates these other pathogenic functions. Long-lived plasma cells (CD20-negative) are spared.
Mechanism: Bind glucocorticoid receptor → suppress NF-κB and AP-1 → reduce cytokines, adhesion molecules, MHC expression → induce lymphocyte apoptosis
Glucocorticoids affect every step of inflammation—more broadly than any targeted agent. Rapid onset makes them invaluable for flares. But receptors are ubiquitous → extensive side effects with chronic use. Goal: use for induction, then transition to steroid-sparing agents.
Why We Can't Cure Autoimmunity
Current therapies suppress the effector phase of autoimmunity—they don't fix the underlying tolerance defect. When immunosuppression is withdrawn, autoreactive lymphocytes that escaped tolerance checkpoints remain in the repertoire. Memory T and B cells persist. Long-lived plasma cells continue secreting autoantibodies. The disease relapses because the source of autoreactivity was never eliminated.
- Memory problem: Memory cells persist for decades and resist deletion
- Epitope spreading: New autoantigens recruited over time → broader attack
- Plasma cell sanctuary: Bone marrow plasma cells are CD20-negative, long-lived
- Tissue damage: Chronic inflammation → fibrosis → permanent organ damage
- Tregs decline: Chronic inflammation may deplete/exhaust regulatory populations
Tolerance induction (rather than just suppression) is the holy grail. Approaches under investigation: antigen-specific tolerance using peptide-MHC complexes or tolerogenic dendritic cells; CAR-Treg therapy to suppress specific autoantigen responses; low-dose IL-2 to expand endogenous Tregs; HSCT to "reset" the immune system. Until these mature, we manage autoimmunity with chronic suppression—balancing disease control against infection risk and drug toxicity.